TDM검사 신빙도조사 결과보고 (2002)

Abstract

Three trials of external quality assessment for Therapeutic Drug Monitoring (TDM) subcommittee of Korean Association of Quality Assurance for Clinical Pathology (KAQACP) were performed in 2002. Participating laboratories were 79 similar to the previous year. Response rates were 96.3% for 1st, 2nd, and third trials. In the first trial, 20 test items among 27 ones were responded from as least from one laboratory as follows: acetaminophen, amikacin, amitriptyline, carbamazepine, cyclosporine, digoxin, free phenytoin, gentamicin, lithium, methotrexate, phenobarbital, phenytoin, primidone, quinidine, salicylate, tacrolimus (FK-506), theophylline, tobramycin, valproic acid and vancomycin. In the second and third trial, the test items were same with those of 1st trial except the exclusion of quinidine. We included tacrolimus with a whole blood control material in addition to cyclosporine from the first trial. The most common test items were valproic acid, digoxin, phenytoin, carbamazepine, theophylline, and phenobarbital which were peformed in more than 77% of participating laboratories. The most widely used TDM analyzer was Abbott TDx/TDxFLx (56%), but its proportion were decreased slightly comparing with the previous years. In conclusion, we added tacrolimus from the year of TDM proficiency testing in 2002 and found grossly similar pattern comparing with those of previous years.